Latest news with #ARSPharma
Yahoo
21-02-2025
- Business
- Yahoo
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
Approximately five months after launch, the inclusion of neffy on these three additional formularies has expanded access to half of all patients and caregivers managing Type 1 allergic reactions, bringing the total number of formulary platforms covering neffy to 30 SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that Cigna Healthcare, Navitus Health Systems and OptumRx, through their Group Purchasing Organization (GPO) Emisar, have added ® (epinephrine nasal spray) to their National Formularies. 'Millions of patients nationwide now have improved access to through their commercial insurance, thanks to coverage from leading pharmaceutical benefit managers and health plans. will also be available at the lowest branded copay for patients insured by OptumRx, Cigna Healthcare, and Navitus Health Systems - without the need for prior authorizations or restrictive step therapies,' said Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharma. 'As a result, more patients will qualify for the low copay price of $25 for , when they apply the ARS Pharma copay assistance, and healthcare providers can prescribe it without the need for additional paperwork.' 'This announcement also underscores the critical demand for a nasal spray epinephrine option within the severe allergy community and we remain committed to ensuring continued access for as many patients and caregivers as possible. While Emisar represents both OptumRx and UnitedHealthcare as their GPO at this time only OptumRx has agreed to the Emisar terms. ARS Pharma is working closely with UnitedHealthcare, as one of the country's largest healthcare providers, to add to their formulary as soon as possible,' said Lowenthal. The addition of to these formularies improves coverage for the approximately 20 million people who have been diagnosed and treated for the more severe Type I allergic reactions that may lead to anaphylaxis and need epinephrine therapy to protect themselves in their daily lives. To assist patients in navigating coverage and affordability challenges, ARS Pharma offers a number of programs for patients and caregivers. For more information, visit 2 mg is for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.). It is the first and only FDA-approved epinephrine nasal spray that provides a needle-free alternative to traditional injectable epinephrine. It's simple and intuitive design enables rapid administration, helping patients and caregivers act quickly and confidently, and the small size is easy to carry. Additionally, has a shelf-life of 30 months and temperature exclusions up to 122 degrees Fahrenheit. The supplemental NDA for 1 mg, for children over four years of age who weigh 15 to 30 kg, has a Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2025. Based on review timelines and subject to approval, product availability of 1 mg is expected by the end of May 2025. ARS Pharma anticipates that by the epinephrine prescription renewal period, which occurs over the summer for many children in the United States, that school age children who meet the weight and age criteria will have access to . About is an intranasal epinephrine product for patients with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis. INDICATION AND IMPORTANT SAFETY INFORMATION FOR (epinephrine nasal spray) INDICATION 2 mg is indicated for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater. IMPORTANT SAFETY INFORMATION It is recommended that patients are prescribed and have immediate access to two nasal sprays at all times. In the absence of clinical improvement or if symptoms worsen after initial treatment, administer a second dose of in the same nostril with a new nasal spray starting 5 minutes after the first dose. is for use in the nose only. Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required. Absorption of may be affected by underlying structural or anatomical nasal conditions. Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris or produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics. The presence of a sulfite in should not deter use. may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including . Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson's disease, diabetes, renal impairment. Epinephrine should be administered with caution in patients with these conditions, including elderly patients and pregnant women. Adverse reactions to may include throat irritation, intranasal paresthesia, headache, nasal discomfort, feeling jittery, paresthesia, fatigue, tremor, rhinorrhea, nasal pruritus, sneezing, abdominal pain, gingival pain, hypoesthesia oral, nasal congestion, dizziness, nausea, and vomiting. These are not all of the possible side effects of . To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA-1088 or For additional information on , please see Full Prescribing Information at About Type I Allergic Reactions Including Anaphylaxis Type I allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine auto-injectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 40 million people in the United States who experience Type I allergic reactions. Of this group, over the last three years, approximately 20 million people have been diagnosed and treated for severe Type I allergic reactions that may lead to anaphylaxis, but (in 2023, for example) only 3.2 million filled their active epinephrine auto-injector prescription, and of those, only half consistently carry their prescribed auto-injector. Even if patients or caregivers carry an auto-injector, more than half either delay or do not administer the device when needed in an emergency. About ARS Pharmaceuticals, Inc. ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing 2 mg (trade name EUR in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit Forward-Looking Statements Statements in this press release that are not purely historical in nature are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: the expected impact from the inclusion of on OptumRx, Cigna Healthcare and Navitus Health Systems' National Formularies; ARS Pharmaceuticals' expectation that other payors, such as UnitedHealthcare, will agree to terms to provide access to and the timing by which they will provide such access, the critical demand for a nasal spray epinephrine option, the expectation that will save lives; the effectiveness of ; the expected timing for product availability of 1 mg; and other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as 'anticipate,' 'expects,' 'if,' 'may,' 'potential,' 'on track to,' 'plans,' 'will,' 'would,' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon ARS Pharmaceuticals' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: potential safety and other complications from ; ARS Pharmaceuticals' reliance on its licensing partners; the ability to maintain regulatory approval forin its currently approved indication and to obtain and maintain regulatory approval for for additional indications; the labelling for in any future indication or patient population, if approved; the scope, progress and expansion of developing and commercializing ; the potential for governments and payors to delay, limit or deny coverage for ; the size and growth of the market therefor and the rate and degree of market acceptance thereof vis-à-vis intramuscular injectable products; ARS Pharmaceuticals' ability to protect its intellectual property position; and the impact of government laws and regulations. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption 'Risk Factors' in ARS Pharmaceuticals' Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange Commission ('SEC') on November 13, 2024. These documents can also be accessed on ARS Pharmaceuticals' website at by clicking on the link 'Financials & Filings' under the 'Investors & Media' tab. The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharmaceuticals assumes no obligation and does not intend to update these forward-looking statements, except as required by law. For more information, visit and follow us on LinkedIn and X. ARS Investor Contact:Justin ChakmaARS Pharmaceuticalsjustinc@ ARS Media Contact:Christy CurranSam Brown Inc.615.414.8668christycurran@ in to access your portfolio
Yahoo
18-02-2025
- Health
- Yahoo
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
Oral presentation on an efficacy study conducted in Japanese patients comparing anaphylaxis symptoms during oral food challenge with as the initial treatment compared to site historical data on intramuscular auto-injectors, antihistamines and inhalers; patients receiving had lower symptom scores within 10 minutes, supporting as a needle-free option for management of anaphylaxis was shown to be in the safe and efficacious range for children four years or older who weigh more than 15 kilograms Findings in Chinese studies confirms U.S. data and bracketed pharmacokinetic (PK) and pharmacodynamic (PD) profiles, demonstrate comparable efficacy and safety under various conditions including self-administration, allergic rhinitis, infectious rhinitis, in allergy challenges and with repeat dosing, compared with intermuscular injection SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that nine presentations will be featured at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting, February 28 to March 3, in San Diego, California. The oral presentation and posters will feature data from a wide range of studies, including pharmacokinetics and pharmacodynamics of intranasal epinephrine under normal and various conditions, physiological responses between adults and children who are administered epinephrine, and the pre-treatment journey of patients with allergic conditions. In addition to the presentations, ARS Pharma will participate in and host a variety of onsite activities during the meeting. 'We look forward to sharing additional findings from our comprehensive clinical research program with the broader allergy community at AAAAI and expect that the data will continue to build on the existing robust data on the efficacy and safety of intranasal epinephrine administration,' said Sarina Tanimoto, MD, PhD, Co-Founder and Chief Medical Officer of ARS Pharma the maker of (epinephrine nasal spray), the first and only FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.). 'As one of the leading companies actively conducting research in this critical space, we remain committed to advancing the scientific knowledge base of epinephrine so we can contribute to the allergy community.' The complete list of presentations and meeting activities is below. Abstracts can be viewed at Attendees are encouraged to visit the ARS Pharma booth (#1315), oral and poster presentations as well as the product theatre to learn more about . Oral Presentation – March 1, 2025 Time: 2:45 p.m. - 2:55 p.m. PST Title: Superior Efficacy of Epinephrine Nasal Spray for the Relief of Symptoms Following an Oral Food Challenge Speaker: Kyohei Takahashi, MD, MPH, PhD Room: Convention Center, Upper Level, Room 6B Poster ID: 571 Poster Presentations – March 1, 2025 Poster Presentation #1 Time: 9:45 a.m. - 10:45 a.m. PST Title: Pharmacokinetics and Pharmacodynamics of Single Dose of Epinephrine Nasal Spray and Manual Intramuscular Injections via HCP and Self-administration in Chinese Subjects Under Normal Conditions Authors: Yun Liu, MD, Shumin Wang, PhD, Miao Yu, MD, PhD, Pingya Hu, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD Poster ID: 297 Poster Presentation #2 Time: 9:45 a.m. - 10:45 a.m. PST Title: Persistence to Treatment in Patients with Allergic Conditions Requiring Epinephrine Auto-Injector Prescription (EAI Rx) Authors: Autumn Burnette, MD, Raffi Tachdjian, MD, Nicole M. Chase, MD, Sarina Tanimoto, MD, PhD, Ayman Kafal, PhD, MPH Poster ID: 302 Poster Presentation #3 Time: 9:45 a.m. - 10:45 a.m. PST Title: Pharmacokinetics of Epinephrine Nasal Spray under Various Conditions Authors: David M. Fleischer, MD, John Oppenheimer, MD, David Bernstein, MD, Thomas B. Casale, MD, Jonathan M. Spergel, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD Poster ID: 290 Poster Presentation #4 Time: 9:45 a.m. - 10:45 a.m. PST Title: Difference in Physiology Between Adults and Children in Response to Epinephrine Administration Authors: Matthew J. Greenhawt, MD, David M. Fleischer, MD, Thomas B. Casale, MD, Michael A. Kaliner, MD, Neetu Talreja, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD Poster ID: 289 Poster Presentation #5 Time: 9:45 a.m. - 10:45 a.m. PST Title: Understanding the Pre-Treatment Journey of Patients with Allergic Conditions: Insights from Patient Demographics and Diagnostic Pathways Authors: Raffi Tachdjian, MD, Autumn Burnette, MD, Nicole M. Chase, MD, Sarina Tanimoto, MD, PhD, Ayman Kafal, PhD, MPH Poster ID: 291 Poster Presentation #6 Time: 9:45 a.m. - 10:45 a.m. PST Title: Pharmacokinetics and Pharmacodynamics of Single Dose of Epinephrine Nasal Spray and Manual Intramuscular Injection in Chinese Subjects Under Allergic Rhinitis Conditions Authors: Jianting Wang, MD, PhD, Shumin Wang, PhD, Miao Yu, MD, PhD, Jiaowei Lu, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD Poster ID: 318 Poster Presentation #7 Time: 9:45 a.m. - 10:45 a.m. PST Title: Total Nasal Symptom Scores Remain Consistent in Response to Repeated Nasal Allergen Challenges Authors: Anne K. Ellis, MD, Michael A. Kaliner, MD, Carlos A. Camargo, Jr., MD, DrPH, John Oppenheimer, MD, David Bernstein, MD, Thomas B. Casale, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD Poster ID: 483 Poster Presentation #8 Time: 9:45 a.m. - 10:45 a.m. PST Title: Pharmacokinetics and Pharmacodynamics of Repeat Dose of Epinephrine Nasal Spray and Manual Intramuscular Injection in Chinese Subjects Under Normal Conditions Authors: Shumin Wang, PhD, Jianting Wang, MD, PhD, Miao Yu, MD, PhD, Jiaowei Lu, MD, Richard Lowenthal, MSc, Sarina Tanimoto, MD, PhD Poster ID: 317 Onsite Activities Joint Congress Opening Ceremony and Welcome Reception Date: February 27, 2025 Time: 4:15 p.m. - 5:45 p.m. PST Location: Convention Center - Ground Level Room 6A Non-CME Corporate Forum (Product Theatre) Date: February 27, 2025 Time: 6:30 p.m. - 8:30 p.m. PST Location: Marriott Marquis San Diego Marina - North Tower, Lobby Level Grand Ballroom Salon 4 Exhibit Booth Date: February 28-March 2, 2025 Location: #1315 About is an intranasal epinephrine product for patients with Type I allergic reactions due to insect stings or bites, foods, medicinal products, other allergens, as well as idiopathic or exercise induced anaphylaxis that could lead to life-threatening anaphylaxis. INDICATION AND IMPORTANT SAFETY INFORMATION FOR (epinephrine nasal spray) INDICATION2 mg is indicated for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater. IMPORTANT SAFETY INFORMATIONIt is recommended that patients are prescribed and have immediate access to two nasal sprays at all times. In the absence of clinical improvement or if symptoms worsen after initial treatment, administer a second dose of in the same nostril with a new nasal spray starting 5 minutes after the first dose. is for use in the nose only. Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required. Absorption of may be affected by underlying structural or anatomical nasal conditions. Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris or produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics. The presence of a sulfite in should not deter use. may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including . Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson's disease, diabetes, renal impairment. Epinephrine should be administered with caution in patients with these conditions, including elderly patients and pregnant women. Adverse reactions to may include throat irritation, intranasal paresthesia, headache, nasal discomfort, feeling jittery, paresthesia, fatigue, tremor, rhinorrhea, nasal pruritus, sneezing, abdominal pain, gingival pain, hypoesthesia oral, nasal congestion, dizziness, nausea, and vomiting. These are not all of the possible side effects of . To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA-1088 or For additional information on , please see Full Prescribing Information at About Type I Allergic Reactions Including Anaphylaxis Type I allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine auto-injectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 40 million people in the United States who experience Type I allergic reactions. Of this group approximately 20 million people have been diagnosed and treated for severe Type I allergic reactions that may lead to anaphylaxis, but (in 2023, for example) only 3.2 million filled their active epinephrine auto-injector prescription, and of those, only half consistently carry their prescribed auto-injector. Even if patients or caregivers carry an auto-injector, more than half either delay or do not administer the device when needed in an emergency. About ARS Pharmaceuticals, Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The company is commercializing 2 mg (trade name EUR in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, other allergens, as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit ARS Pharma Investor Contact: Justin ChakmaARS Pharmajustinc@ ARS Pharma Media Contact:Christy CurranSam Brown Inc. 615.414.8668christycurran@ in to access your portfolio
Yahoo
05-02-2025
- Health
- Yahoo
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the Oppenheimer 35th Annual Healthcare Conference being held virtually. Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma and Eric Karas, Chief Commercial Officer of ARS Pharma will participate in a fireside chat on Wednesday, February 12, 2025, at 2:40 p.m. ET. Company management will also participate in one-on-one meetings with investors. A live webcast of the fireside chat will be available here, and in the Investors & Media section of the Company's website. A replay of the webcast will be archived on the Company's website for 90 days. About ARS Pharmaceuticals, Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing 2 mg (trade name EUR in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit ARS Investor Contacts:Justin ChakmaARS Pharmaceuticalsjustinc@ ARS Media Contact:Christy CurranSam Brown in to access your portfolio
